Critical commentary on the association between thiazolidinedione use and dementia risk in patients with type 2 diabetes

J Diabetes. 2023 Jul;15(7):627-628. doi: 10.1111/1753-0407.13409. Epub 2023 May 8.

Authors

Uzayr Wasif¹, Usmaan Al-Shehab^{2

3}, David F Lo^{1

2

3}

Affiliations

¹ Department of Biology, Rutgers, the State University of New Jersey, New Brunswick, New Jersey, USA.
² Department of Medicine, Rowan University School of Osteopathic Medicine, Stratford, New Jersey, USA.
³ American Preventive Screening & Education Association (APSEA), Stratford, New Jersey, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Dementia* / chemically induced
Dementia* / epidemiology
Diabetes Mellitus, Type 2* / chemically induced
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / adverse effects
Thiazolidinediones* / adverse effects

Substances

2,4-thiazolidinedione
Thiazolidinediones
Hypoglycemic Agents